Skip to main content

Table 5 Multivariate Cox Regression for Survival

From: Locally ablative treatment of breast cancer liver metastases: identification of factors influencing survival (the Mammary Cancer Microtherapy and Interventional Approaches (MAMMA MIA) study)

a. Multivariate Cox Regression for Survival, Factors available at treatment initiation only

Variable set

Hazard ratio

95 % CI

p-value

Extrahepatic metastases (yes)

2.13

0.97 - 4.64

0.058

Liver volume (≥ 1376 mL)

2.25

1.01 - 5.02

0.047

Maximum diameter of liver metastases (≥ 3.9 cm)

3.12

1.39 - 7.02

0.006

Number of liver metastases (≥ 6)

1.48

0.69 - 3.14

0.312

Lines of chemotherapy (≥ 3)

2.48

1.15 - 5.36

0.021

Bone metastases only (yes)

1.56

0.70 - 3.47

0.279

Liver volume (≥ 1376 mL)

2.01

0.93 - 4.36

0.076

Maximum diameter of liver metastases (≥ 3.9 cm)

3.1

1.37 - 7.02

0.007

Number of liver metastases (≥ 6)

1.51

0.72 - 3.20

0.278

Lines of chemotherapy (≥ 3)

2.6

1.14 - 5.92

0.023

b. Multivariate Cox Regression for Survival, All Factors (Pre- and Posttherapeutic)

Variable set

Hazard ratio

95 % CI

p-value

Extrahepatic metastases (yes)

1.05

0.43 - 2.58

0.92

Liver volume (≥ 1376 mL)

2.17

0.90 - 5.22

0.084

Maximum diameter of liver metastases (≥ 3.9 cm)

3.1

1.31 - 7.36

0.01

Number of liver metastases (≥ 6)

1.13

0.49 - 2.59

0.782

Lines of chemotherapy (≥ 3)

1.81

0.83 - 3.97

0.138

Under local control in FU (yes)

0.29

0.11 - 0.73

0.009

Best response overall (OR, RECIST)

0.21

0.08 - 0.57

0.002

Bone metastases only (yes)

1.06

0.46 - 2.44

0.89

Liver volume (≥ 1376 mL)

2.16

0.92 - 5.03

0.075

Maximum diameter of liver metastases (≥ 3.9 cm)

3.05

1.22 - 7.61

0.017

Number of liver metastases (≥ 6)

1.12

0.48 - 2.59

0.796

Lines of chemotherapy (≥ 3)

1.8

0.80 - 4.01

0.154

Under local control in FU (yes)

0.29

0.12 - 0.70

0.006

Best response overall (OR, RECIST)

0.21

0.08 - 0.52

0.001

  1. Multivariate cox models were created on the basis of significant and non-interacting factors from univariate analysis with one model exclusively analyzing factors available prior to treatment (5 a.) and a separate model including all factors including those available at follow-up only (5 b.). Additionally, due to interaction of these variables, separate models were created to analyze the survival impact of either overall extrahepatic disease or bone metastases as the sole extrahepatic tumor manifestation